Cardio Diabetes Master ClassMay 6, 2017 - Beijing, China
As a clinician with an interest in diabetes and cardiovascular disease you are cordially invited to participate in the Cardio Diabetes Master Class.
The program of this Master Class is designed to provide the participants with new information and perspectives on effective strategies to help patients, with diabetes and/or increased cardiovascular risk to reach their treatment goals.
- Saturday, May 6, 2017: 08:30 - 16:30 hrs
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a risk based intervention strategy that targets glucose control and cardiovascular risk factors
- To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
- To provide an expert perspective on the expanding role of RAS blockade in multiple organs in the treatment of patients at increased CV risk
- To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
- To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
Crowne Plaza Beijing Sun Palace - 100028- Yunnan Dasha, North-East Corner of Taiyanggong Bridge, Xibahe, North-East 3rd Ring Road, Chaoyang District, Beijing 100028, P. R. China.
Session 1 - Introduction: Cardio & Metabolic Risk
Co-Chairmen: Prof Lisheng Liu & Prof Xin Gao
- Diabetes and cardiovascular disease risk in China: Lessons from 20 years study of Daqing prevention study - Prof. Guangwei Li, FUWAI Hospital, Beijing
Session 2 - Metabolic Risk and Glycemic management Updates
Co-Chairmen: Prof Yiming Mu & Prof Lisheng Liu
- Glycemic control: Are new Incretin-based treatments changing the fundamentals of diabetes management? - Prof. Jochen Seufert, MD, University Hospital of Freiburg Freiburg, Germany
- T2DM & cardiovascular risk: What are the considerations for glycemic therapy? - Prof. Sanjay Rajagopalan, MD, UH Cleveland Medical Center Cleveland, OH, USA
Session 3 - Cardiovascular Risk, Hypertension & RAS Updates
Co-Chairmen: prof. Changsheng Ma & Prof. Runlin Gao
- Blood Pressure 2017: Translating latest insights to clinical practice- key lessons from SPRINT/HOPE-3 - Prof. Richard Hobbs, MD, University of Oxford, Oxford, United Kingdom
- RAS inhibition, Cornerstone in CV therapy: Review on current role in management of hypertension and heart failure - Prof. Luis Ruilope, MD, Hospital 12 de Octubre, Madrid, Spain
Session 4 - How to session: brief updates and guidance for practice
Co-Chairmen: prof Dalong Zhu, Prof Zhaosu Wu
- Multidisciplinary management of CV risk: models and lessons from Spain - Prof. Luis Ruilope, MD, Madrid, Spain
- Achieving glycemic targets: When do we need combination therapy? - Prof. Jochen Seufert, MD, Freiburg, Germany
- Blood Pressure control: which targets to use? - Prof. Richard Hobbs, MD, Oxford, United Kingdom
- T2DM in high CV risk patients: what are the implications for therapy - Prof. Sanjay Rajagopalan, MD, Cleveland, OH, USA
Session 5 - Ask the expert: workshop sessions
Co-Chairmen: prof Dalong Zhu, Prof Zhaosu Wu, Prof Yiming Mu, Prof Changsheng Ma
- Case discussions addressing day-to-day clinical issues in the management of patients with increased cv risk and type 2 diabetes in small groups with individual faculty members
Participation to this Cardio Diabetes Master Class is open to physicians from China, Taiwan and Hong Kong - (cardiologists, internal medicine and diabetologists).
Confirmation of participation is upon discretion of the PACE foundation.
Register for participation and attendance of the Cardio Diabetes Master Class via the Register here web link:
This educational program is funded by an unrestricted educational grant provided by Takeda Pharmaceuticals